GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow ...
Strategic focus shifted from cautious spending and scaling to a full embrace of growth, especially with the 170% test volume growth target for 2026 and a doubling of sales reps. Guidance language ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results